Patent Number: 6,251,938

Title: Phenylethylamine derivatives

Abstract: This invention is directed to compounds of the following formula: ##STR1## wherein m is from 0-4; X is O or S; Y is halogeno; R.sub.1 is hydrogen or C.sub.1-4 alkyl; R.sub.2 is hydrogen, C.sub.1-4 alkyl or optionally substituted propargyl; and R.sub.3 and R.sub.4 are each independently hydrogen, C.sub.1-8 alkyl, C.sub.6-12 aryl, C.sub.6-12 cycloalkyl or C.sub.6-12 aralkyl, R.sub.5 is hydrogen or C.sub.1-4 alkyl; and pharmaceutically acceptable salts thereof, provided that when X is O, R.sub.2 is optionally substituted propargyl. This invention is also directed to the use of these compounds for treating depression, Attention Deficit Disorder (ADD), Attention Deficit and Hyperactivity Disorder (ADHD), Tourette's Syndrome, Alzheimer's Disease and other dementia's such as senile dementia, dementia of the Parkinson's type, vascular dementia and Lewy body dementia. This invention is further directed to a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.

Inventors: Chorev; Michael (Jerusalem, IL), Goren; Tamar (Rehovot, IL), Herzig; Yacov (Ra'ananna, IL), Sterling; Jeffrey (Jerusalem, IL), Weinstock-Rosin; Marta (Jerusalem, IL), Youdim; Moussa B. H. (Haifa, IL)

Assignee: Teva Pharmaceutical Industries, Ltd.,

International Classification: C07C 271/42 (20060101); C07C 271/56 (20060101); C07C 271/00 (20060101); A61K 031/27 (); C07C 333/00 (); C07C 271/00 ()

Expiration Date: 06/26/2018